Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis

被引：12

作者：

Sugimoto, Takeya ^{[1
]}

Fujimoto, Daichi ^{[1
,2
]}

Sato, Yuki ^{[2
]}

Tamiya, Motohiro ^{[3
]}

Yokoi, Takashi ^{[4
]}

Taniguchi, Yoshihiko ^{[5
]}

Hino, Aoi ^{[6
]}

Hata, Akito ^{[7
]}

Uchida, Junji ^{[8
]}

Fukuda, Yasushi ^{[9
]}

Hara, Satoshi ^{[10
]}

Kanazu, Masaki ^{[11
]}

Matsumoto, Hirotaka ^{[12
]}

Kokubo, Masaki ^{[13
]}

Yamamoto, Nobuyuki ^{[1
]}

机构：

[1] Wakayama Med Univ, Internal Medicine3, 811-1, Kimiidera, Wakayama, Japan

[2] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Japan

[3] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

[4] Hyogo Coll Med, Dept Thorac Oncol, Nishinomiya, Japan

[5] Natl Hosp Org Kinki, Chuo Chest Med Ctr, Dept Internal Med, Sakai, Japan

[6] Chiba Univ, Dept Respirol, Grad Sch Med, Chiba, Japan

[7] Kobe Minimally Invas Canc Ctr, Div Thorac Oncol, Kobe, Japan

[8] Osaka Gen Med Ctr, Dept Resp Med, Osaka, Japan

[9] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Japan

[10] Itami City Hosp, Dept Resp Med, Itami, Japan

[11] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Japan

[12] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Japan

[13] Kobe City Med Ctr, Dept Radiat Oncol, Gen Hosp, Kobe, Japan

来源：

LUNG CANCER | 2022年 / 171卷

关键词：

Immune -checkpoint inhibitors; PD-L1; Durvalumab; Non -small cell lung cancer; Radiation; Pneumonitis; CONCURRENT THORACIC RADIOTHERAPY; PHASE-III; DOCETAXEL; CHEMOTHERAPY; CISPLATIN; NIVOLUMAB; TRIAL;

D O I：

10.1016/j.lungcan.2022.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: Durvalumab was safe and effective in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in a phase 3 trial (PACIFIC trial). Although a history of radiation pneumonitis (RP) has been reported to increase the risk of exacerbation of pneumonitis associated with programmed death-1 axis inhibitors, the detailed clinical results of durvalumab treatment in patients with baseline grade 1 RP were not reported in the PACIFIC trial. Therefore, we aimed to evaluate the safety and effectiveness of durvalumab therapy in these patients. Materials and methods: This was a multicenter prospective cohort study involving 35 patients. Patients were eligible if they met the following criteria: inoperable stage III NSCLC, administration of durvalumab within 42 days after CCRT using platinum-based chemotherapy, no disease progression after CCRT, Eastern Cooperative Oncology Group performance status of 0-1, and presence of grade 1 RP at baseline. We assessed the effectiveness and safety of durvalumab with a minimum 1-year follow-up period for all patients. Results: Thirty-five patients were enrolled in our study from February 2019 to December 2019. The median progression-free survival was 11.4 months (95 % confidence interval, 7.1 months-not reached), and the median overall survival was not reached. Eleven (31 %) patients had grade >= 2 pneumonitis/RP, 10 (28 %) developed grade 2 pneumonitis/RP, and 1 (3 %) developed grade 5 pneumonitis/RP. Five (14 %) patients experienced treatment-related grade >= 3 adverse events. Conclusion: Durvalumab might be safe and effective in patients with stage III NSCLC with baseline grade 1 RP following chemoradiotherapy.

引用

页码：3 / 8

页数：6

共 19 条

[1]

[Anonymous], 2020, CANC MED, DOI DOI 10.21037/ATM.2020.01.66

[2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[6] Radiation-Induced Lung Injury Assessment and Management [J].

Hanania, Alexander N. ;

Mainwaring, Walker ;

Ghebre, Yohannes T. ;

Hanania, Nicola A. ;

Ludwig, Michelle .

CHEST, 2019, 156 (01) :150-162

[7] Cancer treatment and survivorship statistics, 2019 [J].

Miller, Kimberly D. ;

Nogueira, Leticia ;

Mariotto, Angela B. ;

Rowland, Julia H. ;

Yabroff, K. Robin ;

Alfano, Catherine M. ;

Jemal, Ahmedin ;

Kramer, Joan L. ;

Siegel, Rebecca L. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) :363-385

[8] Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer A National Cancer Database Survey [J].

Morgensztern, Daniel ;

Ng, Shean Huey ;

Gao, Feng ;

Govindan, Ramaswamy .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) :29-33

[9] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer [J].

Nakanishi, Yu ;

Masuda, Takeshi ;

Yamaguchi, Kakuhiro ;

Sakamoto, Shinjiro ;

Horimasu, Yasushi ;

Nakashima, Taku ;

Miyamoto, Shintaro ;

Tsutani, Yasuhiro ;

Iwamoto, Hiroshi ;

Okada, Morihito ;

Hattori, Noboru ;

Fujitaka, Kazunori ;

Miyata, Yoshihiro ;

Hamada, Hironobu .

RESPIRATORY INVESTIGATION, 2019, 57 (05) :451-459

[10] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].

Rittmeyer, Achim ;

Barlesi, Fabrice ;

Waterkamp, Daniel ;

Park, Keunchil ;

Ciardiello, Fortunato ;

von Pawel, Joachim ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Kowalski, Dariusz M. ;

Dols, Manuel Cobo ;

Cortinovis, Diego L. ;

Leach, Joseph ;

Polikoff, Jonathan ;

Barrios, Carlos ;

Kabbinavar, Fairooz ;

Frontera, Osvaldo Aren ;

De Marinis, Filippo ;

Turna, Hande ;

Lee, Jong-Seok ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

He, Pei ;

Chen, Daniel S. ;

Sandler, Alan ;

Gandara, David R. .

LANCET, 2017, 389 (10066) :255-265

← 1 2 →